Who are Ongoing cART regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): DOR/3TC/TDF, Dolutegravir / Lamivudine Pill, Maraviroc, Darunavir/r, Doravirine + tenofovir DF + lamivudine, Atazanavir/ Stavidine / Lamivudine, Raltegravir, tenofovir/emtricitabine.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ongoing-cart-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

Ongoing cART regimen — Competitive Intelligence Brief

Ongoing cART regimen (Ongoing cART regimen) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiretroviral. Area: Infectious Diseases.

phase 3 Antiretroviral Infectious Diseases Small molecule Live · refreshed every 30 min

Target snapshot

Ongoing cART regimen (Ongoing cART regimen) — ViiV Healthcare. cART regimens combine multiple antiretroviral drugs to suppress HIV replication by targeting different stages of the viral life cycle.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ongoing cART regimen TARGET	Ongoing cART regimen	ViiV Healthcare	phase 3	Antiretroviral
DOR/3TC/TDF	DOR/3TC/TDF	Prism Health North Texas	marketed	Antiretroviral combination therapy (NNRTI + NRTI + NtRTI)	HIV reverse transcriptase
Dolutegravir / Lamivudine Pill	Dolutegravir / Lamivudine Pill	Charlotte-Paige Rolle, MD	marketed	Antiretroviral combination (INSTI + NRTI)	HIV integrase; HIV reverse transcriptase
Maraviroc, Darunavir/r	Maraviroc, Darunavir/r	Catholic University of the Sacred Heart	marketed	Antiretroviral combination (CCR5 antagonist + protease inhibitor)	CCR5 co-receptor (maraviroc); HIV protease (darunavir)
Doravirine + tenofovir DF + lamivudine	Doravirine + tenofovir DF + lamivudine	Instituto Mexicano del Seguro Social	marketed	Antiretroviral combination (NNRTI + NRTIs)	HIV reverse transcriptase
Atazanavir/ Stavidine / Lamivudine	Atazanavir/ Stavidine / Lamivudine	Bristol-Myers Squibb	marketed	Antiretroviral combination therapy (protease inhibitor + nucleoside reverse transcriptase inhibitors)	HIV protease, HIV reverse transcriptase
Raltegravir, tenofovir/emtricitabine	Raltegravir, tenofovir/emtricitabine	University of California, San Francisco	marketed	Antiretroviral combination therapy (integrase inhibitor + nucleoside/nucleotide reverse transcriptase inhibitors)	HIV integrase, HIV reverse transcriptase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiretroviral class)

A.O. Ospedale Papa Giovanni XXIII · 1 drug in this class
National Institute of Allergy and Infectious Diseases (NIAID) · 1 drug in this class
Pfizer · 1 drug in this class
University of Guadalajara · 1 drug in this class
ViiV Healthcare · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ongoing cART regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/ongoing-cart-regimen. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab